Par, Purdue Settle IP Claims In OxyContin Antitrust MDL

Law360, New York (September 25, 2013, 9:49 PM EDT) -- Par Pharmaceutical Cos. Inc. has settled a suit alleging its proposed generic OxyContin infringed Purdue Pharma LP patents for a tamper-resistant form of the widely abused painkiller, according to a consent judgment Tuesday laying to rest claims that were rolled into antitrust multidistrict litigation in New York federal court.

Par acknowledged under the settlement that the generic oxycodone for which it was seeking U.S. Food and Drug Administration approval infringed Purdue's five patents and agreed not to market, sell or distribute its drug until a set...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.